About The Study: In this post hoc secondary analysis of 10,678 participants with atherosclerotic cardiovascular disease from a randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of heart attack, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population.
Authors: Mark B. Effron, M.D., of the University of Queensland-Ochsner Clinical School in New Orleans, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2023.3364)